Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nurofen refers to a range of ibuprofen formulations developed by Reckitt Benckiser, designed for the treatment of pain, inflammation, and fever. As a nonsteroidal anti-inflammatory drug (NSAID), the active ingredient ibuprofen works by inhibiting the cyclooxygenase enzymes COX-1 and COX-2, which are critical for the biosynthesis of prostaglandins that mediate pain and inflammatory responses. Reckitt Benckiser has specifically focused on developing advanced delivery formats, such as ibuprofen lysine and ibuprofen sodium salts, as well as liquid-filled capsules. These formulations are engineered to provide faster disintegration and systemic absorption compared to standard ibuprofen acid, thereby facilitating a more rapid onset of analgesic action for over-the-counter use.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Nurofen.